» Articles » PMID: 28842313

A Facile Approach to Functionalizing Cell Membrane-coated Nanoparticles with Neurotoxin-derived Peptide for Brain-targeted Drug Delivery

Overview
Specialty Pharmacology
Date 2017 Aug 27
PMID 28842313
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

The blood brain barrier separates the circulating blood from the extracellular fluid in the central nervous system and thus presents an essential obstacle to brain transport of therapeutics. Herein, we report on an effective brain-targeted drug delivery system that combines a robust red blood cell membrane-coated nanoparticle (RBCNP) with a unique neurotoxin-derived targeting moiety. The RBCNPs retain the complex biological functions of natural cell membranes while exhibiting physicochemical properties that are suitable for effective drug delivery. CDX peptide is derived from candoxin and shows high binding affinity with nicotinic acetylcholine receptors (nAChRs) expressed on the surface of brain endothelial cells. Through a facile yet robust approach, we successfully incorporate CDX peptides onto the surface of RBCNPs without compromising the peptide's brain targeting ability. The resulting CDX-RBCNPs show promising brain targeting efficiency both in vitro and in vivo. Using a glioma mouse model, we demonstrate that doxorubicin-loaded CDX-RBCNPs have superior therapeutic efficacy and markedly reduced toxicity as compared to the nontargeted drug formulations. While RBCNPs are used as a model system to evaluate the surface modification approach, the reported method can be readily generalized to various types of cell membrane-derived nanocarriers for broad medical applications.

Citing Articles

Red blood cells-derived components as biomimetic functional materials: Matching versatile delivery strategies based on structure and function.

Liu H, Li Y, Wang Y, Zhang L, Liang X, Gao C Bioact Mater. 2025; 47:481-501.

PMID: 40034412 PMC: 11872572. DOI: 10.1016/j.bioactmat.2025.01.021.


Biomimetic Nanoparticle Based Targeted mRNA Vaccine Delivery as a Novel Therapy for Glioblastoma Multiforme.

Ahmed T, Alam K AAPS PharmSciTech. 2025; 26(3):68.

PMID: 39984771 DOI: 10.1208/s12249-025-03065-z.


Cell Membrane- and Extracellular Vesicle-Coated Chitosan Methacrylate-Tripolyphosphate Nanoparticles for RNA Delivery.

Liew W, Alkaff S, Leong S, Yee M, Hou H, Czarny B Int J Mol Sci. 2025; 25(24.

PMID: 39769486 PMC: 11678704. DOI: 10.3390/ijms252413724.


Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication.

Mengyuan H, Aixue L, Yongwei G, Qingqing C, Huanhuan C, Xiaoyan L J Nanobiotechnology. 2024; 22(1):604.

PMID: 39370518 PMC: 11456251. DOI: 10.1186/s12951-024-02835-4.


Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases.

Ozceylan O, Sezgin-Bayindir Z ACS Omega. 2024; 9(33):35223-35242.

PMID: 39184484 PMC: 11340000. DOI: 10.1021/acsomega.4c01774.